OSTEOSARCOMA RECURRENT
Clinical trials for OSTEOSARCOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OSTEOSARCOMA RECURRENT trials appear
Sign up with your email to follow new studies for OSTEOSARCOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to halt returning bone cancer
Disease control OngoingThis study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. It includes 63 people aged 12 to 40. The goal is to see if the combination can stop the cancer from growing or delay its return.
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo tackles returning bone cancer before surgery
Disease control OngoingThis early-phase trial tests the safety and effectiveness of the immune drug nivolumab (Opdivo) alone or combined with the chemo drug azacitidine (Vidaza) in people whose osteosarcoma has come back and can be surgically removed. About 21 participants will receive the drugs before…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy shows promise for tough bone cancer
Disease control OngoingThis study tests whether combining two drugs, regorafenib and nivolumab, can help people with osteosarcoma (a type of bone cancer) that has returned or not responded to previous treatments. About 48 participants aged 5 and older will receive the combination. The main goal is to s…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC